Fierce Pharma ------ Branded drugmakers weren't the only ones working through a tumultuous 2016. Generics companies faced pricing pressure, too. And while branded companies suffer pricing pain on costly cutting-edge therapies, generics outfits feel the pinch with already-thin margins, making pressure all the more agonizing. How is the industry responding? By consolidating and hoping to save money, for one. Take a look at Fierce Pharma's 2014 ranking, and it's clear that some companies have made leaps too big to depend on organic growth alone. Take Mylan, which topped the 2016 list, up from No. 4 in 2014. It wrapped up a big deal last year, a $7.2 billion buyout of Sweden’s Meda, which helped it bulk up in over-the-counter drug offerings and win a presence in some emerging markets new to the U.S.-based company. That acquisition followed a series of others in recent years, and Mylan is now working to cut loose up to 3,500 employees as it aims to reap savings from that deal spree. To learn more click on the picture below to read the article.
Share on Facebook
Share on Twitter
I'm busy working on my blog posts. Watch this space!